RecentRCT

STRIVE/ReSTORE post hoc pooled analysis

Rezafungin Versus Caspofungin in Candidaemia and Invasive Candidiasis: A Post Hoc Pooled Analysis of Phase 2 and Phase 3 Trials.

Mycoses, 2026 · Post hoc pooled analysis of prior randomized phase 2/3 trials, including China extension

Population: 372 pooled adults; day-30 mortality denominators 161 versus 178
Intervention: Weekly rezafungin
Comparator: Daily caspofungin
Primary outcome: Day-30 mortality in the pooled analysis
Result: 20% versus 22%; weighted difference −2.4 percentage points (95% CI −11.2 to 6.4).

What the trial found

Mortality estimates were imprecise; negative blood cultures occurred sooner in the rezafungin group.

Clinical interpretation

Reused trial participants are not independent replication; the post hoc analysis does not prove survival superiority or shorter safe duration.

Low certainty

Clinical Context & Relevant Topics (1)

Disease Reference

Candidemia & Invasive Candidiasis

ICU recognition and treatment of candidemia and invasive candidiasis, including source control, repeat cultures, step-down therapy and metastatic infection.

View Topic Context →